KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Common Equity (2016 - 2025)

Historic Common Equity for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $559.5 million.

  • Xenon Pharmaceuticals' Common Equity fell 2986.89% to $559.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.5 million, marking a year-over-year decrease of 2986.89%. This contributed to the annual value of $754.9 million for FY2024, which is 1864.58% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Common Equity stood at $559.5 million, which was down 2986.89% from $634.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Common Equity's 5-year high stood at $927.9 million during Q4 2023, with a 5-year trough of $248.9 million in Q3 2021.
  • In the last 5 years, Xenon Pharmaceuticals' Common Equity had a median value of $686.9 million in 2023 and averaged $642.9 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Common Equity surged by 22099.03% in 2021, and later crashed by 2986.89% in 2025.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Common Equity stood at $550.0 million in 2021, then soared by 31.17% to $721.5 million in 2022, then rose by 28.61% to $927.9 million in 2023, then decreased by 18.65% to $754.9 million in 2024, then dropped by 25.88% to $559.5 million in 2025.
  • Its last three reported values are $559.5 million in Q3 2025, $634.0 million for Q2 2025, and $704.0 million during Q1 2025.